子宮癌藥物及診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依癌症類型、藥物、診斷、地區及競爭格局分類，2021-2031年）

全球子宮頸癌治療和診斷市場預計將從 2025 年的 232.1 億美元成長到 2031 年的 325.7 億美元，複合年成長率為 5.81%。

該市場涵蓋用於治療子宮內膜癌和子宮肉瘤的藥物、外科手術和診斷技術。其成長主要受肥胖和停經後婦女荷爾蒙失衡等風險因素增加以及政府改善醫療基礎設施和推廣早期篩檢計畫等措施的推動。

儘管存在這些積極因素，但先進免疫療法和標靶藥物遞送系統的高成本仍然是獲得治療的一大障礙，尤其是在發展中地區。儘管疾病負擔日益加重，但這項經濟挑戰依然存在：美國癌症協會估計，2024年美國將新增67,880例宮內膜癌病例。因此，與長期照護相關的經濟限制仍然是市場進一步擴張的一大障礙。

市場促進因素

推動市場成長的關鍵因素是新型標靶治療和免疫療法的快速監管核准，這些療法正在重塑進行性子宮內膜癌的標準治療方案。監管機構對免疫查核點抑制劑的核准不斷增加；例如，基於一項納入718名患者的DUO-E臨床試驗的結果，FDA於2024年6月核准Durvalumab聯合化療用於治療錯配修復缺陷型腫瘤。這些批准使製藥公司能夠將生物製藥商業化，作為復發性疾病領域傳統化療的替代方案，從而刺激對腫瘤藥物研發管線的進一步投資。

此外，由於人口老化和生活方式因素，全球子宮惡性腫瘤的發生率不斷上升，因此亟需拓展診斷和治療方法。這一成長趨勢在國際上也十分明顯。加拿大癌症協會於2024年5月發布的報告預測，該國每年新增子宮癌病例將達8,700例。這種日益成長的發病率帶來了巨大的商業性回報，葛蘭素史克(GSK)報告稱，其子宮內膜癌治療藥物Gempari僅在2024年第三季度的銷售額就達到了1.02億英鎊，便印證了這一點。

市場挑戰

先進免疫療法和標靶藥物遞送系統相關的巨額成本是限制子宮頸癌市場成長的主要因素。在醫療資源匱乏和醫療覆蓋不足的地區，這些藥物的高昂價格限制了病患的取得和使用，迫使醫療機構採用價格較低廉的傳統療法。這種經濟障礙阻礙了新治療通訊協定的廣泛應用，從而降低了先進治療藥物生產商的獲利潛力。

鑑於疾病的嚴重後果，在亟需有效介入的地區，這些經濟限制的影響尤其顯著。美國癌症協會預測，到2024年，子宮內膜癌將在美國造成約13,250人死亡，凸顯了疾病的迫切臨床需求。然而，長期治療和新型藥物方案的高昂費用持續阻礙市場滲透，導致臨床需求與經濟可行性之間持續存在差距，並減緩了該領域的整體商業性擴張。

市場趨勢

針對HER2陽性疾病的抗體藥物複合體（ADC）的興起，標誌著子宮惡性腫瘤（尤其是漿液性癌）治療領域的重要進展。為了支持這一趨勢，FDA於2024年4月基於DESTINY-PanTumor02試驗加速核准了famtrastuzumab deruxtecan-nxki上市，該試驗顯示其客觀緩解率達51.4%。這種治療方法透過抗體將細胞毒性藥物直接遞送至癌細胞，與傳統療法相比，可最大限度地降低全身毒性，並為已用盡標準療法的患者提供了一種新的精準醫療選擇。

同時，機器人輔助微創手術技術的興起正在重新定義子宮切除術和分期手術的治療標準。這些平台為外科醫生提供了更佳的控制力和視野，這對於肥胖患者群體尤其重要，因為肥胖是該疾病的高發人群，同時也有助於減少術後併發症。直覺外科公司（Intuitive Surgical）2024年10月發布的報告也印證了人們對這項技術的日益依賴。報告顯示，全球達文西手術系統手術量年增約18%，這將有助於醫療機構應對不斷成長的患者群。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球子宮頸癌藥物及診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 癌症類型（子宮內膜腺癌、腺鱗癌、乳頭狀漿液性癌、子宮肉瘤）
  • 依治療方法（手術、免疫療法、放射線治療、化療、其他）
  • 透過診斷方法（切片檢查、骨盆超音波、子宮鏡檢查、刮除手術、 電腦斷層掃描）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美子宮頸癌藥物及診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲子宮頸癌藥物及診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區子宮頸癌藥物及診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東及非洲子宮頸癌藥物及診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲子宮頸癌藥物及診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球子宮癌藥物及診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Uterine Cancer Therapeutics & Diagnostics Market is projected to expand from USD 23.21 Billion in 2025 to USD 32.57 Billion by 2031, registering a CAGR of 5.81%. This market includes pharmaceutical agents, surgical interventions, and diagnostic technologies aimed at managing endometrial cancer and uterine sarcoma. Growth is largely fueled by the increasing prevalence of risk factors such as obesity and hormonal imbalances in postmenopausal women, alongside government efforts to improve healthcare infrastructure and promote early screening programs.

Despite these positive drivers, the high cost of advanced immunotherapies and targeted drug delivery systems poses a major barrier to accessibility, particularly in developing regions. This economic challenge persists even as the disease burden grows; the American Cancer Society estimated that 67,880 new cases of uterine corpus cancer would be diagnosed in the United States in 2024. Consequently, financial constraints related to long-term care remain a significant impediment to the broader expansion of the market.

Market Driver

A primary engine for market growth is the accelerated regulatory approval of novel targeted therapies and immunotherapies, which are reshaping the standard of care for advanced endometrial carcinoma. Regulatory bodies are increasingly clearing immune checkpoint inhibitors, such as the FDA's June 2024 approval of durvalumab with chemotherapy for mismatch repair deficient tumors, a decision supported by the DUO-E clinical trial of 718 patients. These authorizations allow pharmaceutical developers to commercialize biologics that replace traditional chemotherapy in recurrent disease settings, incentivizing further investment in the oncology pipeline.

Additionally, the rising global incidence of uterine malignancies, driven by aging populations and lifestyle factors, necessitates an expansion of diagnostic and therapeutic availability. This growing burden is evident internationally, with the Canadian Cancer Society's May 2024 report projecting 8,700 new uterine cancer diagnoses in Canada for the year. This increasing prevalence translates into substantial commercial returns, as demonstrated by GSK's report that sales of the endometrial cancer treatment Jemperli reached £102 million in the third quarter of 2024 alone.

Market Challenge

The significant expense associated with advanced immunotherapies and targeted drug delivery systems acts as a major restraint on the uterine cancer market's growth. In areas with insufficient healthcare funding or limited insurance coverage, the high price of these agents restricts patient access and adoption, compelling healthcare providers to utilize older, less expensive alternatives. This economic barrier limits the widespread implementation of newer treatment protocols and subsequently reduces the revenue potential for manufacturers of advanced therapeutics.

These financial constraints are particularly impactful given the severe outcomes of the disease, which require effective intervention. The American Cancer Society projected approximately 13,250 deaths from uterine corpus cancer in the United States in 2024, highlighting the urgent clinical need. However, the prohibitive costs linked to long-term management and novel drug regimens continue to hinder market penetration, maintaining a gap between clinical requirements and economic feasibility that slows the sector's overall commercial expansion.

Market Trends

The rise of antibody-drug conjugates (ADCs) targeting HER2-positive disease represents a significant evolution in the management of uterine malignancies, especially serous carcinomas. Validating this trend, the FDA granted accelerated approval in April 2024 to fam-trastuzumab deruxtecan-nxki based on the DESTINY-PanTumor02 trial, which demonstrated an objective response rate of 51.4%. This approach delivers cytotoxic payloads directly to cancer cells via antibodies, minimizing systemic toxicity compared to traditional methods and offering a new precision medicine avenue for patients who have exhausted standard treatments.

Simultaneously, the adoption of robot-assisted minimally invasive surgical techniques is redefining the standard for hysterectomy and staging procedures. These platforms offer surgeons greater dexterity and visualization, which is particularly beneficial for the obese patient demographic often associated with this condition, while also reducing post-operative complications. The expanding reliance on this technology is underscored by Intuitive Surgical's October 2024 report, which noted an approximate 18% year-over-year growth in worldwide da Vinci procedures, supporting healthcare providers in managing increasing patient volumes.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
  • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others)
  • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By Diagnostics
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By Diagnostics
  • 6.3.2. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By Diagnostics
  • 6.3.3. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By Diagnostics
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By Diagnostics
  • 7.3.2. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By Diagnostics
  • 7.3.3. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By Diagnostics
  • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By Diagnostics
  • 7.3.5. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By Diagnostics

8. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By Diagnostics
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By Diagnostics
  • 8.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By Diagnostics
  • 8.3.3. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By Diagnostics
  • 8.3.4. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapeutics
      • 8.3.4.2.3. By Diagnostics
  • 8.3.5. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapeutics
      • 8.3.5.2.3. By Diagnostics

9. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By Diagnostics
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By Diagnostics
  • 9.3.2. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By Diagnostics
  • 9.3.3. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By Diagnostics

10. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By Diagnostics
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By Diagnostics
  • 10.3.2. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By Diagnostics
  • 10.3.3. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ariad Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Becton, Dickinson & Co.
• 15.4. GlaxoSmithKline Plc
• 15.5. Merck & Co., Inc.
• 15.6. Novartis AG
• 15.7. Sanofi SA
• 15.8. Siemens Healthineers AG.
• 15.9. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer